QJM : monthly journal of the Association of Physicians
-
Meta Analysis
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Vit-K antagonists are the therapy of choice to prevent thromboembolic events due to atrial fibrillation since many years. New oral anticoagulants (NOA) showed encouraging results vs. warfarin but there are no data directly comparing different NOA. We performed an adjusted indirect meta-analysis. ⋯ Overall superiority of NOA over warfarin is largely influenced by the reduction of HS. Dabigatran 150 mg/twice daily seems to have the best risk/benefit profile.